Kamada Ltd. (NASDAQ:KMDA) stock identified change of 28.57% away from 52-week low price and recently located move of -21.13% off 52-week high price. It has market worth of $255.63M. KMDA stock has been recorded -2.23% away from 50 day moving average and 8.96% away from 200 day moving average. Moving closer, we can see that shares have been trading -10.65% off 20-day moving average.
On Jan. 7, 2020, Kamada Ltd. (NASDAQ:KMDA) a plasma-derived protein therapeutics company, declared preliminary and unaudited total revenue for the fourth quarter and full-year 2019. Total revenue for the fourth quarter of 2019 is expected to be between $31.4 million and $32.4 million. Total revenue for full-year 2019 is expected to be between $126.5 million and $127.5 million. Kamada’s anticipated full-year 2019 revenue is in line with the Company’s prior revenue guidance of $125 million to $130 million, which was initially provided at the end of 2018.
For full-year 2020, the Company expects total revenue to be in the range of $132 million and $137 million. The year-over-year revenue growth in 2020 as compared to 2019 is expected to be driven by increased sales in the U.S. of KEDRAB®, Kamada’s anti-rabies IgG product, as well as increased sales of the Company’s Proprietary IgG products portfolio in international markets, and expected growth of the Distribution segment in Israel. As previously communicated, based on Takeda’s inventory planning for GLASSIA®, and as reflected in the recent extension of Kamada’s strategic supply agreement with Takeda for this product, Kamada does not anticipate increased sales of GLASSIA to Takeda in 2020 as compared to 2019, although the number of patients treated with GLASSIA in the U.S. is expected to continue to grow.
The anticipated increase in Proprietary Product sales in international markets is an important step towards the Company’s goal of effectively utilizing the excess capacity at its plant following the planned transition of GLASSIA manufacturing to Takeda in 2021. In 2020, the expected change in product sales mix, as well as reduced plant utilization, is anticipated to result in an overall decrease in the Propriety Products segment’s full-year gross margins of approximately three to five percentage points as compared to 2019.
In addition, due to the planned acceleration in 2020 of the recently initiated pivotal Phase 3 InnovAATe clinical trial evaluating the safety and efficacy of the Company’s proprietary inhaled Alpha-1 Antitrypsin (AAT) therapy for the treatment of AAT Deficiency, Kamada expects an approximately 15% to 18% increase in R&D expenses in 2020, as compared to 2019.
The Healthcare sector company, Kamada Ltd. noticed change of -4.97% to $6.31 along volume of 120283 shares in recent session compared to an average volume of 55.31K. The stock observed return of -7.61% in 5 days trading activity. The stock was at -14.73% over one month performance. KMDA’s shares are at 24.21% for the quarter and driving a 22.29% return over the course of the past year and is now at -7.61% since this point in 2018. The average volatility for the week at 2.59% and for month was at 2.51%. There are 40.51M shares outstanding and 22.07M shares are floated in market.